Shannon Stokley1, Amanda Cohn, Nidhi Jain, Mary M McCauley. 1. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. sstokley@cdc.gov
Abstract
OBJECTIVES: To determine vaccination coverage at selected ages and by birth cohort and to assess whether all indicated vaccines were administered during vaccination visits. DESIGN: Population-based cross-sectional study. SETTING: National Immunization Survey-Teen 2009 telephone interview. PARTICIPANTS: United States adolescents aged 13 to 17 years with provider-reported vaccination histories (N = 20 066). MAIN OUTCOME MEASURES: Among all adolescents and by birth cohort: coverage estimates for 3 childhood vaccines (measles-containing, hepatitis B, and varicella) and 3 adolescent vaccines (tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis, meningococcal-containing, and human papillomavirus for girls) at selected ages. RESULTS: By age 11 years, most adolescents had obtained the childhood vaccines. Receipt of a tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis vaccine at ages 11 to 12 years increased significantly from the 1991 to 1996 birth cohort (33.8% vs 68.2%, P < .001); receipt of meningococcal-containing vaccine at ages 11 to 12 years increased significantly from the 1993 to 1996 birth cohort (8.4% vs 50.0%, P < .001). Among girls, receipt of human papillomavirus vaccine at ages 11 to 12 years increased significantly from the 1994 to 1996 birth cohort (11.1% vs 30.5%, P < .001). Overall, 54.9% of adolescents received at least 1 vaccination visit at ages 11 to 12 years. Among adolescents who made a vaccination visit at ages 11 to 12 years and were eligible for vaccination, 19.5% did not receive tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis, 60.9% did not receive meningococcal-containing, and 62.4% did not receive human papillomavirus vaccines. CONCLUSIONS: Receipt of vaccines at the recommended ages of 11 to 12 years appears to be increasing; however, providers often do not administer all indicated vaccines during a vaccination visit.
OBJECTIVES: To determine vaccination coverage at selected ages and by birth cohort and to assess whether all indicated vaccines were administered during vaccination visits. DESIGN: Population-based cross-sectional study. SETTING: National Immunization Survey-Teen 2009 telephone interview. PARTICIPANTS: United States adolescents aged 13 to 17 years with provider-reported vaccination histories (N = 20 066). MAIN OUTCOME MEASURES: Among all adolescents and by birth cohort: coverage estimates for 3 childhood vaccines (measles-containing, hepatitis B, and varicella) and 3 adolescent vaccines (tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis, meningococcal-containing, and human papillomavirus for girls) at selected ages. RESULTS: By age 11 years, most adolescents had obtained the childhood vaccines. Receipt of a tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis vaccine at ages 11 to 12 years increased significantly from the 1991 to 1996 birth cohort (33.8% vs 68.2%, P < .001); receipt of meningococcal-containing vaccine at ages 11 to 12 years increased significantly from the 1993 to 1996 birth cohort (8.4% vs 50.0%, P < .001). Among girls, receipt of human papillomavirus vaccine at ages 11 to 12 years increased significantly from the 1994 to 1996 birth cohort (11.1% vs 30.5%, P < .001). Overall, 54.9% of adolescents received at least 1 vaccination visit at ages 11 to 12 years. Among adolescents who made a vaccination visit at ages 11 to 12 years and were eligible for vaccination, 19.5% did not receive tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis, 60.9% did not receive meningococcal-containing, and 62.4% did not receive human papillomavirus vaccines. CONCLUSIONS: Receipt of vaccines at the recommended ages of 11 to 12 years appears to be increasing; however, providers often do not administer all indicated vaccines during a vaccination visit.
Authors: Megan C Lindley; Jenny Jeyarajah; David Yankey; C Robinette Curtis; Lauri E Markowitz; Shannon Stokley Journal: Hum Vaccin Immunother Date: 2016-03-22 Impact factor: 3.452
Authors: Pieter Remes; Veronica Selestine; John Changalucha; David A Ross; Daniel Wight; Silvia de Sanjosé; Saidi Kapiga; Richard J Hayes; Deborah Watson-Jones Journal: Vaccine Date: 2012-06-22 Impact factor: 3.641
Authors: Deborah Watson-Jones; Kathy Baisley; Riziki Ponsiano; Francesca Lemme; Pieter Remes; David Ross; Saidi Kapiga; Philippe Mayaud; Silvia de Sanjosé; Daniel Wight; John Changalucha; Richard Hayes Journal: J Infect Dis Date: 2012-06-18 Impact factor: 5.226